81 filings
Page 3 of 5
8-K
b1jejh2 8b
9 Apr 21
Other Events
7:30am
8-K
x652zcvl90rfb
16 Mar 21
Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors
4:30pm
8-K
qxmza590302y9bfm
12 Mar 21
Iterum Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
7:15am
8-K
9swfghed l0g3
22 Feb 21
Departure of Directors or Certain Officers
4:30pm
8-K
n4onppz0c9or9hmt
11 Feb 21
Iterum Therapeutics plc Announces Exercise of Underwriter’s Option to Purchase Additional Ordinary Shares
12:00am
8-K
gbwc7hv ndpl4r
10 Feb 21
Iterum Therapeutics plc Announces $35.0 Million Registered
8:54am
8-K
ov46ojo2mso
5 Feb 21
Iterum Therapeutics plc Announces $10 Million Bought Deal
5:09pm
8-K
44usd2
1 Feb 21
Iterum Therapeutics Announces Collaboration with EVERSANA to Support Oral Sulopenem Launch
5:00pm
8-K
flqxx8tzw
28 Jan 21
Iterum Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem
4:16pm
8-K
wnjgzg8xks7lu m5i5
23 Dec 20
Iterum Therapeutics Announces Transition of Michael Dunne, M.D. to Strategic Advisor and Member of the Board of Directors
7:20am
8-K
9mwkyvobxs2rtnfi
21 Dec 20
Iterum Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
5:15pm
8-K
4pqeqj1tmb
16 Nov 20
Iterum Therapeutics Reports Third Quarter 2020 Financial Results
7:00am
8-K
f94gabbds c2ju144f
27 Oct 20
Iterum Therapeutics Announces Pricing of $17.5 Million Upsized Public Offering
5:29pm
8-K
26je4 xgwotlh2wu
30 Sep 20
Iterum Therapeutics Announces Positive Pre-NDA Meeting with FDA for Sulopenem for Treatment of Uncomplicated Urinary Tract Infections
4:15pm
8-K
emx 41rxwzatnx2tecf
25 Sep 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:15pm
8-K/A
vvm3o71pp1d9ncubr0rt
2 Sep 20
Iterum Therapeutics Announces Revised Results of Rights Offering
7:15am
8-K
f5lhp9ezbbwn17 f3rtt
1 Sep 20
Iterum Therapeutics Announces Expiration and Preliminary Results of Rights Offering
4:05pm
8-K
e7rqdfxr yk
11 Aug 20
Iterum Therapeutics Commences Rights Offering
8:38am
8-K
dueip0dp9ksstxd
6 Aug 20
Iterum Therapeutics Reports Second Quarter 2020 Financial Results
7:00am
8-K
7mkcghf3
17 Jul 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm